Opinion|Videos|August 5, 2024
Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
A panel of experts discuss combination regimens with BTK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What emerging evidence is there for combination therapies of BTK inhibitors with new and existing therapies to enhance treatment efficacy in CLL?
Advertisement
Related to this article
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
4
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
5